Document Detail


Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure.
MedLine Citation:
PMID:  22733835     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
AimsBiochemical marker testing has improved the evaluation and management of patients with cardiovascular diseases over the past decade. Natriuretic peptides (NPs), used in clinical practice to assess cardiac dysfunction, exhibit many limitations, however. We used an unbiased proteomics approach for the discovery of novel diagnostic plasma biomarkers of heart failure (HF).Methods and resultsA proteomics pipeline adapted for very low-abundant plasma proteins was applied to clinical samples from patients admitted with acute decompensated HF (ADHF). Quiescin Q6 (QSOX1), a protein involved in the formation of disulfide bridges, emerged as the best performing marker for ADHF (with an area under the receiver operator characteristic curve of 0.86, 95% confidence interval: 0.79-0.92), and novel isoforms of NPs were also identified. Diagnostic performance of QSOX1 for ADHF was confirmed in 267 prospectively collected subjects of whom 76 had ADHF. Combining QSOX1 to B-type NP (BNP) significantly improved diagnostic accuracy for ADHF by particularly improving specificity. Using thoracic aortic constriction in rats, QSOX1 was specifically induced within both left atria and ventricles at the time of HF onset.ConclusionThe novel biomarker QSOX1 accurately identifies ADHF, particularly when combined with BNP. Through both clinical and experimental studies we provide lines of evidence for a link between ADHF and cardiovascular production of QSOX1.
Authors:
Alexandre Mebazaa; Griet Vanpoucke; Gregoire Thomas; Katleen Verleysen; Alain Cohen-Solal; Marc Vanderheyden; Jozef Bartunek; Christian Mueller; Jean-Marie Launay; Natalie Van Landuyt; Filip D'hondt; Elisabeth Verschuere; Caroline Vanhaute; Robin Tuytten; Lies Vanneste; Koen De Cremer; Jan Wuyts; Huw Davies; Piet Moerman; Damien Logeart; Corinne Collet; Brice Lortat-Jacob; Miguel Tavares; Wouter Laroy; James L Januzzi; Jane-Lise Samuel; Koen Kas
Related Documents :
12047795 - Risk stratification and prevention of sudden death in hypertrophic cardiomyopathy.
16647885 - Prediction of arrhythmic events with positron emission tomography: parepet study design...
8443205 - Effects of triiodothyronine and vasopressin on cardiac function and myocardial blood fl...
18559335 - Primary prevention of sudden cardiac death using implantable cardioverter defibrillators.
17700215 - Predictors and clinical significance of angiographically detected distal embolization a...
7349945 - Evaluation of transluminal angioplasty of chronic coronary artery stenosis. value and l...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-6-24
Journal Detail:
Title:  European heart journal     Volume:  -     ISSN:  1522-9645     ISO Abbreviation:  -     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-6-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Anesthesia and Intensive Care, U942 Inserm, Paris Diderot University, Lariboisière Hospital, 2 rue Ambroise Paré, 75010 Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Swe...
Next Document:  The future of simulation technologies for complex cardiovascular procedures.